



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	O. F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/674,092	74,092 02/27/2001		Marcus Keep	30-200P	1549
2292	7590	04/20/2004		EXAMINER	
BIRCH S PO BOX		KOLASCH & BIR	MOHAMED, ABDEL A		
		A 22040-0747	ART UNIT	PAPER NUMBER	
				1653	

DATE MAILED: 04/20/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

.3	Application No.	Applicant(s)
Advisory Action	09/674,092	KEEP ET AL.
•	Examiner	Art Unit
	Abdel A. Mohamed	1653
The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence address
THE REPLY FILED 03 March 2004 FAILS TO PLACE T Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applic a timely filed amendment which	ation. A proper reply to a
PERIOD FOR RE	EPLY [check either a) or b)]	
<ul> <li>a)</li></ul>	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF The date on which the petition under 37 CF	ng date of the final rejection.  HE FINAL REJECTION. See MPEP  FR 1.136(a) and the appropriate extension.
fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment. See 37 C	of extension and the corresponding amoust the shortened statutory period for reply se later than three months after the ma	ount of the fee. The appropriate extension originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF	Brief must be filed within the portion of the Brief must be filed within the portion of the Brief must be successful.	eriod set forth in of the appeal.
2. The proposed amendment(s) will not be entered be	ecause:	
(a) 🛛 they raise new issues that would require furthe	er consideration and/or search (	see NOTE below);
(b) they raise the issue of new matter (see Note b	•	
(c)  they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the
(d) M they present additional claims without canceling	ng a corresponding number of f	inally rejected claims.
NOTE: See Continuation Sheet.		
3. Applicant's reply has overcome the following reject	ion(s):	
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:	reconsideration has been consi	dered but does NOT place the
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly
7. For purposes of Appeal, the proposed amendments explanation of how the new or amended claims we	(s) a)⊠ will not be entered or b ould be rejected is provided belo	☐ will be entered and an wor appended.
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected: <u>1-10</u> .		
Claim(s) withdrawn from consideration:		
8. The drawing correction filed on is a) appr	oved or b) disapproved by t	he Examiner.
9. Note the attached Information Disclosure Statemen		
10. ☐ Other:	, , , , , , , , , , , , , , , , , , ,	Christyphus S.J. low
	SUF 1	CHRISTOPHER S. F. LOW PERVISORY PATENT EXAMINER ECHNOLOGY CENTER 1800

## continuation Sheet (PTOL-303)

Continuation of 2. NOTE: It is noted that Applicant has amended claims 1, 3-6, 8 and 10 and have added claims 11 and 12. Applicant's remarks and 1.132 declaration filed 3/3/04 are considered as to the unamended claims and they are not persuasive because Applicant's arguments and the declaration are reflected to the proposed amendment rather than the rejected claims per se. Claim 1 as amended is changed from "at least 0.1% by weight of the total composition" to --from 0.1% to 90% by weight of the total composition--. In claims 3-6 and 8 the addition of "wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition". Also, in claim 6, the addition of various mode of administration, and in newly submitted claims 11 and 12, the addition of improved method for treating various diseases such as Alzheimer's, Parkinson's, HIV, etc. (claim 11), and a method for inducing systemic immunosuppression in patients (claim 12) by administering the pharmaceutical composition claimed. Thus, the claims as amended are very brooad in scope because they are directed to a wide range of cyclosporine concentrations (i.e. from 0.1 to 90% by weight of the total composition) and to various mode of admiistrations and to various treatment of diseases and conditions which are not dealt with previously, and as such would require further consideration and search. Therefore, since the amendment and declaration filed 3/3/04 were not entered, for the reasons discussed above, all the previous rejections are maintained for the reasons of record.